Ambu Weighing Options For CardioPump After Panel Votes Against Approval
This article was originally published in The Gray Sheet
Executive SummaryAmbu is considering its next step in pursuing U.S. marketing of the CardioPump, following a 6-3 vote against approval by FDA's Circulatory System Devices Panel at a June 29 meeting in Rockville, Maryland.
You may also be interested in...
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.